Phosphatidylethanolamine (PE) is an important membrane component for supporting activated protein C anticoagulant activity but has little influence on prothrombin activation. This difference constitutes a potential mechanism for selective inhibition of the protein C anticoagulant pathway by lupus anticoagulants and/or antiphospholipid antibodies. In this study, we demonstrate that the presence of PE augments lupus anticoagulant activity. In the plasma of some patients with lupus anticoagulants, activated protein C anticoagulant activity is more potently inhibited than prothrombin activation. As a result, in the presence of activated protein C and PE, these patient plasmas clot faster than normal plasma. Patients with minimal lupus anticoagulant activity are identified whose plasma potently inhibits activated protein C anticoagulant activity. This process is also PE dependent. In three patient plasmas, these phenomena are shown to be due to immunoglobulins. The PE requirement in the expression of activated protein C anticoagulant activity and the PE dependence of some antiphospholipid antibodies provide a mechanistic basis for the selective inhibition of the protein C pathway. Inhibition of activated protein C function may be a common mechanism contributing to increased thrombotic risk in certain patients with antiphospholipid antibodies.
M D Smirnov, D T Triplett, P C Comp, N L Esmon, C T Esmon
Title and authors | Publication | Year |
---|---|---|
Anti-phospholipid antibodies are elevated and functionally active in chronic rhinosinusitis with nasal polyps.
Eide JG, Wu J, Stevens WW, Bai J, Hou S, Huang JH, Rosenberg J, Utz P, Shintani-Smith S, Conley DB, Welch KC, Kern RC, Hulse KE, Peters AT, Grammer LC, Zhao M, Lindholm P, Schleimer RP, Tan BK |
Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology | 2022 |
Diagnosis and management of the antiphospholipid syndrome
S Chaturvedi, KR McCrae |
Blood Reviews | 2017 |
Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers
S Chaturvedi, KR McCrae |
Current Rheumatology Reports | 2017 |
Lupus
WA Khan |
Lupus | 2017 |
Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies
S Hou, H Fölsch, K Ke, JC Mills, R Ramsey-Goldman, M Zhao |
Proceedings of the National Academy of Sciences | 2017 |
Seronegative Antiphospholipid Syndrome with Anti-phosphatidylethanolamine Antibody in a Boy
T Asano, H Narazaki, K Kaizu, K Kuwabara, O Fujino, Y Itoh |
Journal of Nippon Medical School | 2015 |
Synergistic Thrombotic Risk of Antibodies Against Phosphatidylserine and Prothrombin and β-2-Glycoprotein I
H Kim, JE Kim, SM Hwang, HR Lee, KS Han, HK Kim |
Clinical and Applied Thrombosis/Hemostasis | 2013 |
Modeling of human factor Va inactivation by activated protein C
MC Bravo, T Orfeo, KG Mann, SJ Everse |
BMC Systems Biology | 2012 |
Influence of chronic inflammation and autoimmunity on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients
W Plazak, M Pasowicz, M Kostkiewicz, J Podolec, L Tomkiewicz-Pajak, J Musial, P Podolec |
Inflammation Research | 2011 |
Advances in Immunology
E Pinaud, M Marquet, R Fiancette, S Péron, C Vincent-Fabert, Y Denizot, M Cogné |
Advances in Immunology Volume 110 | 2011 |
Cognitive dysfunction and white matter abnormalities in antiphospholipid syndrome
D Erkan, E Kozora, MD Lockshin |
Pathophysiology | 2011 |
Antiphospholipid antibody syndrome—an overview
C Sridevi, PK Raju |
Journal of Indian College of Cardiology | 2011 |
Antiphospholipid antibodies and the protein C pathway
SS Pierangeli, ML Bertolaccini, MA Khamashta, RT Urbanus, B Laat |
Lupus | 2010 |
Basic mechanisms and pathogenesis of venous thrombosis
CT Esmon |
Blood Reviews | 2009 |
Mechanisms of antiphospholipid-induced thrombosis: Effects on the protein C system
D Wahl, A Membre, C Perret-Guillaume, V Regnault, T Lecompte |
Current Rheumatology Reports | 2009 |
Lantibiotics as probes for phosphatidylethanolamine
M Zhao |
Amino Acids | 2009 |
Phosphatidylethanolamine at the endothelial surface of aortic flow dividers
Z Li, CW Wells, CT Esmon, M Zhao |
Journal of Thrombosis and Haemostasis | 2009 |
Phosphatidylethanolamine at the Luminal Endothelial Surface—Implications for Hemostasis and Thrombotic Autoimmunity
Z Li, CW Wells, PE North, S Kumar, CB Duris, JA McIntyre, M Zhao |
Clinical and Applied Thrombosis/Hemostasis | 2009 |
Clinical Immunology
DB Kuhns |
Clinical Immunology | 2008 |
Further evidence of false negative screening for lupus anticoagulants
GW Moore, A Henley, CK Greenwood, S Rangarajan |
Thrombosis Research | 2008 |
The Relationship Between the Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia
DA Hoppensteadt, JM Walenga |
Hematology/Oncology Clinics of North America | 2008 |
Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants
S Liestøl, PM Sandset, MC Mowinckel, F Wisløff |
Journal of Thrombosis and Haemostasis | 2007 |
Metabolic and molecular aspects of ethanolamine phospholipid biosynthesis: the role of CTP:phosphoethanolamine cytidylyltransferase (Pcyt2)
M Bakovic, MD Fullerton, V Michel |
Biochemistry and Cell Biology | 2007 |
[Pathogenesis of the antiphospholipid syndrome]
JL Pasquali, V Poindron, AS Korganow, T Martin |
Presse medicale (Paris, France : 1983) | 2006 |
The Antiphospholipid Syndrome: What are We Really Measuring? How do We Measure it? And How do We Treat it?
TL Ortel |
Journal of Thrombosis and Thrombolysis | 2006 |
A human monoclonal antiprothrombin antibody is thrombogenic in vivo and upregulates expression of tissue factor and E-selectin on endothelial cells
M Vega-Ostertag, X Liu, H Kwan-Ki, P Chen, S Pierangeli |
British Journal of Haematology | 2006 |
Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay
C Gardiner, H Cohen, A Jenkins, SJ Machin, IJ Mackie |
Blood Coagulation & Fibrinolysis | 2006 |
Placental Thrombosis and Spontaneous Fetal Death in Mice Deficient in Ethanolamine Kinase 2
Y Tian, P Jackson, C Gunter, J Wang, CO Rock, S Jackowski |
The Journal of biological chemistry | 2006 |
Effects of membrane and soluble EPCR on the hemostatic balance and endotoxemia in mice
X Zheng, W Li, JM Gu, D Qu, GL Ferrell, NL Esmon, CT Esmon |
Blood | 2006 |
Hughes Syndrome
MA Khamashta |
2006 | |
Anti-prothrombin IgG from patients with anti-phospholipid antibodies inhibits the inactivation of factor Va by activated protein C
M Galli, GM Willems, J Rosing, RM Janssen, JW Govers-Riemslag, P Comfurius, T Barbui, RF Zwaal, EM Bevers |
British Journal of Haematology | 2005 |
Diagnosis of antiphospholipid syndrome
ML Bertolaccini, MA Khamashta, GR Hughes |
Nature Clinical Practice Rheumatology | 2005 |
Inhibition of APC anticoagulant activity on oxidized phospholipid by anti–β2-glycoprotein I monoclonal antibodies
O Safa, CT Esmon, NL Esmon |
Blood | 2005 |
Antiphospholipid syndrome: multiple mechanisms
CG Mackworth-Young |
Clinical & Experimental Immunology | 2004 |
Current Debates in Antiphospholipid Syndrome: The Acquired Antibody-Mediated Thrombophilia
MA Öztürk, IC Haznedaroğlu, M Turgut, H Göker |
Clinical and Applied Thrombosis/Hemostasis | 2004 |
Antiphospholipid antibodies and pregnancy
M Galli, T Barbui |
Best Practice & Research Clinical Haematology | 2003 |
A thrombin-cross-reactive anticardiolipin antibody binds to and inhibits the anticoagulant function of activated protein C
KK Hwang, CD Yang, W Yan, JM Grossman, BH Hahn, PP Chen |
Arthritis & Rheumatism | 2003 |
Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome
S Visvanathan, JK Scott, KK Hwang, M Banares, JM Grossman, JT Merrill, J FitzGerald, RU Chukwuocha, BP Tsao, BH Hahn, PP Chen |
Arthritis & Rheumatism | 2003 |
Hypercoagulable state testing and malignancy screening following venous thromboembolic events
SR Deitcher, MP Gomes |
Vascular medicine (London, England) | 2003 |
Acquired activated protein C resistance, high tissue factor expression, and hyper-homocysteinemia in systemic lupus erythematosus
D Oh, SH Kim, MS Kang, NK Kim, NS Chang, BW Na, SY Chung, S Park, CS Cho |
American Journal of Hematology | 2003 |
Antiphospholipid/antiprotein antibodies, hemostasis-related autoantibodies, and plasma homocysteine as risk factors for a first early pregnancy loss: a matched case-control study
JC Gris, TV Perneger, I Quéré, E Mercier, P Fabbro-Peray, G Lavigne-Lissalde, M Hoffet, H Déchaud, JC Boyer, S Ripart-Neveu, ML Tailland, JP Daurès, P Marès, M Dauzat |
Blood | 2003 |
Low levels of activated protein C in patients with systemic lupus erythematosus do not relate to lupus anticoagulants but to low levels of factor II
MJ Simmelink, JA Fernandez, RH Derksen, JH Griffin, PG de Groot |
British Journal of Haematology | 2002 |
Suppressed intrinsic fibrinolytic activity by monoclonal anti-beta-2 glycoprotein I autoantibodies: possible mechanism for thrombosis in patients with antiphospholipid syndrome
R Takeuchi, T Atsumi, M Ieko, Y Amasaki, K Ichikawa, T Koike |
British Journal of Haematology | 2002 |
Laboratory diagnosis of the antiphospholipid syndrome
F Wisløff, EM Jacobsen, S Liestøl |
Thrombosis Research | 2002 |
The Antiphospholipid Syndrome II
M Ehrenfeld, H Amital, Y Shenfeld |
The Antiphospholipid Syndrome II | 2002 |
Factor V Leiden: a genetic risk factor for thrombotic microangiopathy in patients with normal von Willebrand factor–cleaving protease activity
TJ Raife, SR Lentz, BS Atkinson, SK Vesely, MJ Hessner |
Blood | 2002 |
NEW ASPECTS IN THE PATHOGENESIS AND TREATMENT OF THROMBOTIC THROMBOCYTOPENIC PURPURA AND HEMOLYTIC UREMIC SYNDROME
T Raife, R Montgomery |
Reviews in Clinical and Experimental Hematology | 2001 |
ANTIPHOSPHOLIPID ANTIBODIES AND THE COAGULATION CASCADE
E Anglés-Cano, MC Guillin |
Rheumatic Disease Clinics of North America | 2001 |
The role of tissue factor in the antiphospholipid syndrome
PM Dobado-Berrios, C L�pez-Pedrera, F Velasco, MJ Cuadrado |
Arthritis & Rheumatism | 2001 |
Acquired activated protein C resistance is associated with lupus anticoagulants and thrombotic events in pediatric patients with systemic lupus erythematosus
C Male, L Mitchell, J Julian, P Vegh, P Joshua, M Adams, M David, ME Andrew |
Blood | 2001 |
The Anticoagulant and Anti-inflammatory Roles of the Protein C Anticoagulant Pathway
CT Esmon |
Journal of Autoimmunity | 2000 |
Pathophysiology of the catastrophic antiphospholipid syndrome (CAPS)
DA Triplett, RA Asherson |
American Journal of Hematology | 2000 |
Use of the Dilute Russell Viper Venom Time (dRVVT): Its Importance and Pitfalls
DA Triplett |
Journal of Autoimmunity | 2000 |
Antiphospholipid Antibodies and the Protein C Pathway
NL Esmon, O Safa, MD Smirnov, CT Esmon |
Journal of Autoimmunity | 2000 |
Cardiolipin Enhances Protein C Pathway Anticoagulant Activity
JA Fernández, K Kojima, J Petäjä, TM Hackeng, JH Griffin |
Blood Cells, Molecules, and Diseases | 2000 |
Cardiolipin is a normal component of human plasma lipoproteins
H Deguchi, JA Fernandez, TM Hackeng, CL Banka, JH Griffin |
Proceedings of the National Academy of Sciences | 2000 |
Regulation of blood coagulation
CT Esmon |
Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology | 2000 |
Lipid Oxidation Enhances the Function of Activated Protein C
O Safa, K Hensley, MD Smirnov, CT Esmon, NL Esmon |
The Journal of biological chemistry | 2000 |
Dimers of β 2 -Glycoprotein I Mimic the in Vitro Effects of β 2 -Glycoprotein I-Anti-β 2 -glycoprotein I Antibody Complexes
BC Lutters, JC Meijers, RH Derksen, J Arnout, PG de Groot |
The Journal of biological chemistry | 2000 |
Competition of Annexin V and Anticardiolipin Antibodies for Binding to Phosphatidylserine Containing Membranes
GM Willems, MP Janssen, P Comfurius, M Galli, RF Zwaal, EM Bevers |
Biochemistry | 2000 |
Opposite β2-glycoprotein I requirement for the binding of infectious and autoimmune antiphospholipid antibodies to cardiolipin liposomes is associated with antibody avidity
CM Celli, AE Gharavi, H Chaimovich |
Biochimica et Biophysica Acta (BBA) - Biomembranes | 1999 |
Characterization of IgG monoclonal anti-cardiolipin/anti-beta2GP1 antibodies from two patients with antiphospholipid syndrome reveals three species of antibodies
M Zhu, T Olee, DT Le, RA Roubey, BH Hahn, VL Woods, PP Chen |
British Journal of Haematology | 1999 |
Clinical and laboratory manifestations of anti-factor V antibodies
TL Ortel |
Journal of Laboratory and Clinical Medicine | 1999 |
?2-glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies
M Ieko, K Ichikawa, DA Triplett, E Matsuura, T Atsumi, KI Sawada, T Koike |
Arthritis & Rheumatism | 1999 |
The Effect of Membrane Composition on the Hemostatic Balance
MD Smirnov, DA Ford, CT Esmon, NL Esmon |
Biochemistry | 1999 |
Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset
N Nakamura, T Ban, K Yamaji, Y Yoneda, Y Wada |
Journal of Clinical Investigation | 1998 |
LUPUS ANTICOAGULANTS AND ANTIPHOSPHOLIPID ANTIBODIES
P Thiagarajan, SS Shapiro |
Hematology/Oncology Clinics of North America | 1998 |
Binding of anticardiolipin antibodies to protein C via beta2-glycoprotein I (beta2-GPI): a possible mechanism in the inhibitory effect of antiphospholipid antibodies on the protein C system
T Atsumi, MA Khamashta, O Amengual, S Donohoe, I Mackie, K Ichikawa, T Koike, GR Hughes |
Clinical & Experimental Immunology | 1998 |
Many faces of lupus anticoagulants
DA Triplett |
Lupus | 1998 |
Methods for subtyping lupus anticoagulants
T Exner |
Lupus | 1998 |
Protein C Inhibitor Secreted from Activated Platelets Efficiently Inhibits Activated Protein C on Phosphatidylethanolamine of Platelet Membrane and Microvesicles
J Nishioka, M Ning, T Hayashi, K Suzuki |
The Journal of biological chemistry | 1998 |
A Chimeric Protein C Containing the Prothrombin Gla Domain Exhibits Increased Anticoagulant Activity and Altered Phospholipid Specificity
MD Smirnov, O Safa, L Regan, T Mather, DJ Stearns-Kurosawa, S Kurosawa, AR Rezaie, NL Esmon, CT Esmon |
The Journal of biological chemistry | 1998 |
Antiphospholipid Antibodies Accelerate Plasma Coagulation by Inhibiting Annexin-V Binding to Phospholipids: A “Lupus Procoagulant” Phenomenon
JH Rand, XX Wu, HA Andree, JB Ross, E Rusinova, MG Gascon-Lema, C Calandri, PC Harpel |
Blood | 1998 |
Differential Effects of Anti–β2-Glycoprotein I and Antiprothrombin Antibodies on the Anticoagulant Activity of Activated Protein C
M Galli, L Ruggeri, T Barbui |
Blood | 1998 |
Anti-inflammatory activity of cationic lipids
MC Filion, NC Phillips |
British Journal of Pharmacology | 1997 |
A SIMPLE PROCEDURE THAT INCREASES THE SPECIFICITY OF THE ACTIVATED PROTEIN C RESISTANCE TEST IN SAMPLES CONTAINING ANTIPHOSPHOLIPID ANTIBODIES
EM Jacobsen, F Wisløff |
Thrombosis Research | 1997 |
INFLUENCE OF THE PHOSPHATIDYLETHANOLAMINE (PE) AND BOVINE SERUM ORIGINS ON ANTI-PE ANTIBODY DETECTION BY ELISA
M Berard, MC Boffa |
Thrombosis Research | 1997 |
Les nouvelles cibles des anticorps ≪ antiphospholipides ≫
J Arvieux, L Darnige, F Sarrot-Reynauld |
La Revue de Médecine Interne | 1997 |
Cytokines, Adhesion Molecules, Antiendothelial Cell Autoantibodies and Vascular Disease
DC PhD, CS PhD |
Cardiovascular Pathology | 1997 |
Les “autres” anticorps antiphospholipides
M Sanmarco |
Revue Française des Laboratoires | 1997 |
Review : Abnormalities in the protein C anticoagulant pathway detected by a novel assay using human thrombomodulin
M Mohri, M Sata, K Gomi, Y Maruyama, M Osame, I Maruyama |
Lupus | 1997 |
THE LUPUS ANTICOAGULANT/ANTIPHOSPHOLIPID SYNDROME
SS M.D |
Annual Review of Medicine | 1996 |
False negative screening tests for lupus anticoagulants—An unrecognized problem?
EM Jacobsen, F Wisløff |
Thrombosis Research | 1996 |
Immunology of the antiphospholipid antibody syndrome
RA Roubey |
Arthritis & Rheumatism | 1996 |
The pathophysiology of alveolar osteonecrosis of the jaw: Anticardiolipin antibodies, thrombophilia, and hypofibrinolysis
R Gruppo, CJ Glueck, RE Mcmahon, J Bouquot, BA Rabinovich, A Becker, T Tracy, P Wang |
Journal of Laboratory and Clinical Medicine | 1996 |
Antiphospholipid Antibodies and Associated Clinical Manifestations
M Galli, G Finazzi, T Barbui |
Hematology | 1996 |
Functional Effects of Anticardiolipin Antibodies
EN Harris, SS Pierangeli |
Lupus | 1996 |
Protein C and other Cofactors Involved in the Binding of Antiphospholipid Antibodies: Relation to the Pathogenesis of Thrombosis
PG Groot, DA Horbach, RH Derksen |
Lupus | 1996 |
Immunology of antiphospholipid antibodies and their interaction with plasma proteins
DA Kandiah, SA Krilis |
Lupus | 1996 |
Non β 2 -Glycoprotein I Cofactors for Antiphospholipid Antibodies
M Galli |
Lupus | 1996 |
Impairments of the Protein C System and Fibrinolysis in Infection-Associated Stroke
RF Macko, SF Ameriso, A Gruber, JH Griffin, JA Fernandez, R Barndt, FP Quismorio, JM Weiner, M Fisher |
Stroke; a journal of cerebral circulation | 1996 |
Thrombogenic Properties of Murine Anti-Cardiolipin Antibodies Induced by β 2 Glycoprotein 1 and Human Immunoglobulin G Antiphospholipid Antibodies
SS Pierangeli, XW Liu, G Anderson, JH Barker, EN Harris |
Circulation | 1996 |
Activation of cultured vascular endothelial cells by antiphospholipid antibodies
R Simantov, JM LaSala, SK Lo, AE Gharavi, LR Sammaritano, JE Salmon, RL Silverstein |
Journal of Clinical Investigation | 1995 |
Autoantibodies
MH Lessof, SP Asper |
American Heart Journal | 1960 |